During 1,414,144 person-years of follow-up, cholangiocarcinoma occurred among 222 patients with use of DPP4 inhibitors (incidence rate, 26 per 100,000 patient-years) and among 128 patients with use of sulfonylureas (incidence rate, 23 per 100,000 patient-years)
The API is the peptide itself, but the drug product is the final form that the patient uses, which for most GLP-1s, is a sophisticated autoinjector pen
This hypothesis suggests that by identifying deregulated metabolic pathways, new diagnostic targets can be identified, allowing for the implementation of optimized treatments, including during fetal life, with the aim of providing protective effects for the brain development of individuals with T21 (Fayal Guedj, Bianchi, and Delabar 2014)
These drugs are known as glucagon-like peptide-1 (GLP-1) receptor agonists, and they work by mimicking the naturally occurring GLP-1 hormone in the gut
Kochanowska IE et al
Glucagon receptor activation: Increased hepatic glucose output under some conditions, increased energy expenditure, effects on hepatic lipid metabolism